Latest Intelligence on Pharmaceuticals in United Kingdom

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

Type Product title / description Pub Price
Expert View
Expert View

AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: research shows value of early disease identification, but caution in treatment is advised

At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.

Published By Datamonitor
03 May 2012
CommentWire
CommentWire

Abbott Laboratories: new opportunities from strategic split

The restructuring will allow each new business to develop specific strategies tailored to their distinct markets. This is particularly important for the branded pharmaceutical segment, which is forecast to see low growth over the next five years. Datamonitor expects steady growth from the new medical products company and lower risk for stockholders, itself a primary driver behind this event.

Published By Datamonitor
21 Oct 2011
Expert View
Expert View

Abbott's flu vaccine business may represent a good deal for acquisitive drug makers

According to media reports, pharmaceutical company Abbott Laboratories is looking to auction off its influenza vaccine business in a deal that could be worth up to $600m. Abbott's established link to the Russian flu market and its advanced cell-based technology make the business an attractive prospect for would-be buyers, which may include the likes of GlaxoSmithKline and MedImmune.

Published By Datamonitor
29 Jun 2010
Expert View
Expert View

APA 2012: cariprazine fails to offer a therapeutic breakthrough

Forest and Gedeon's cariprazine is a pharmacologically unique atypical antipsychotic in Phase III development for both schizophrenia and bipolar mania. Data presented at APA 2012 hint that while cariprazine appears to be effective in both indications, its tolerability and failure to address the broader bipolar depression patient population will hinder uptake.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: Forest's latest antidepressants will have diverging fortunes

Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: standout schizophrenia and bipolar depression data for Latuda steal the show

New clinical data were presented at APA 2012 that showed that Latuda is effective as an adjunctive treatment for bipolar depression and may possess a procognitive effect in schizophrenia patients. These findings set Latuda apart from the competition and may allow the drug to shine in a fiercely competitive antipsychotics market.

Published By Datamonitor
15 May 2012
CommentWire
CommentWire

Asthma and eczema: gene discovery could be the missing link

University of Dundee researchers have discovered a new gene that, when mutated, causes eczema and may be associated with asthma. An estimated 10% of the European population carries this mutation, sometimes leading to severe, uncontrolled disease requiring specialist treatment. However, while the discovery holds promise for new treatments for these patients, these drugs are still a long way off.

Published By Datamonitor
23 Mar 2006
ResearchWire
ResearchWire

Asthma treatments: UK favors generics

Published By Datamonitor
26 Feb 2002
CommentWire
CommentWire

AstraZeneca / Renovis: Cerovive offers hope in stroke market

The failure of so many previous stroke trials has meant that those drugs in late stage development are viewed with cautious optimism at best. Nevertheless, the future of Cerovive appears promising for the time being. On an economic and social level, the benefits of the possible launch of an effective and safe neuroprotectant are potentially huge.

Published By Datamonitor
15 Oct 2004

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

No help is available.